CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: 020624

Trade Name: ANZEMET INJECTION

Generic Name: DOLASETRON MESYLATE

Sponsor: HOESCHT MARION ROUSSEL, INC.

Approval Date: 10/11/97

INDICATION(s): FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS, PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING, AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION: 020624

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				
Approvable Letter	X			
Final Printed Labeling				
Medical Review(s)	X			
Chemistry Review(s)	X			
EA/FONSI	X			
Pharmacology Review(s)	X			
Statistical Review(s)	X			
Microbiology Review(s)				
Clinical Pharmacology Biopharmaceutics Review(s)	X			
Bioequivalence Review(s)				
Administrative Document(s)	X			
Correspondence	X			

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: 020624

APPROVAL LETTER

NDA 20-624

Hoechst Marion Roussel, Inc.
Attention: Louise Shibley
Marion Park rive, P.O. Box 9707
Kansas City, MO 64134-0707

SEP 1 1 1997

Dear Ms. Shibley:

Please refer to your new drug application dated February 19, 1996, received February 20, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Anzemet (dolasetron mesylate) Injection.

We acknowledge receipt of your submissions dated March 5, 7, 18, and 27, April 7 and 9, May 12 and 27, June 6, July 29, August 7, and September 4, 1997.

The User Fee goal date for this application is September 19, 1997.

This new drug application provides for a 20 mg/mL formulation indicated for the prevention of chemotherapy-induced emesis, prevention of postoperative nausea and vomiting, and treatment of postoperative nausea and vomiting.

We have completed the review of this application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed marked-up draft labeling. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-624. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. Should an IND not be required to meet your Phase 4 commitments, please submit protocol, data, and final reports to this NDA as correspondences. In addition, we request under 21 CFR 314.81(b)(2)(vii) that you include in your annual report to this application, a status summary of each commitment. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to the Division of Gastrointestinal and Coagulation Drug Products and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications, HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Kati Johnson, Supervisory Consumer Safety Officer, at (301) 443-0487.

Sincerely yours,

/S/ 9/11/97

Paula Botstein, M.D.
Acting Director
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

/S/ 9/5/97

cc:

APPEARS THIS WAY
ON ORIGINAL

Original NDA 20-624
HFD-180/Div. files /S/ 9/5/97
HFD-180/CSO/K.Johnson
HFD-180/AShaw
HFD-180/EDuffy /S/ 9/5/97
HFD-180/JChoudary
HFD-002/ORM (with labeling) /S/ 9/5/97
HFD-103/Office Director
HFD-101/L.Carter
HFD-820/ONDC Division Director
DISTRICT OFFICE
HF-2/Medwatch (with labeling)
HFD-92/DDM-DIAB (with labeling)
HFD-40/DDMAC (with labeling)
HFD-613/OGD (with labeling)
HFD-735/DPE (with labeling) - for all NDAs and supplements for adverse reaction changes.
HFI-20/Press Office (with labeling)

Drafted by: kj/September 4, 1997/c:\wpfiles\cso\n\20624709.0kj

APPROVAL (AP) [with Phase 4 Commitments]

FINAL PRINTED LABELING HAS NOT BEEN SUBMITTED TO THE FDA.

DRAFT LABELING IS NO LONGER BEING SUPPLIED SO AS TO ENSURE ONLY CORRECT AND CURRENT INFORMATION IS DISSEMINATED TO THE PUBLIC.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020624

APPROVABLE LETTER

NDA 20-624

FEB 20 1997

Hoechst Marion Roussel, Inc.
Attention: Louise Shibley
Marion Park Drive, P.O. Box 9707
Kansas City, MO 64134-0707

Dear Ms. Shibley:

Please refer to your new drug application dated February 19, 1996, received February 20, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Anzemet (dolasetron mesylate) Injection.

We acknowledge receipt of your submissions dated April 11 and 22, May 9 and 21, June 3 and 21, November 18, and December 9, 1996. The User Fee goal date for this application is February 20, 1997.

We have completed the review of this application as submitted with draft labeling, and it is approvable. Before this application may be approved, however, it will be necessary for you to provide an adequate response to the following requests for additional chemistry, information and controls information, as conveyed in our letter dated February 6, 1997:

1. Clarify whether the drug product solution is filtered into (as appears to be the case in the batch records in Volume 1.5 of the initial submission, page 114 and Volume 1.7, page 120, respectively) or into a receiving as described in Volume 1.2 (page 30). In addition, include the holding time along with supporting data to ensure product stability and microbial integrity during this period.

2. Please adjust the pH specification from to correspond with the batch capabilities reported in Volume 1.2 (pages 42-53).

3. Include in the container/closure acceptance specifications that the are treated and provide a description of the treatment process.

4. Provide information to demonstrate that the drug product formulation at does not extract possibly toxic substances The compatibility studies described in Volume 1.3 do not address this issue.

In addition, it will be necessary for you to submit final printed labeling (FPL) identical in content to the enclosed marked-up draft labeling. Please submit 20 copies of the final printed labeling, ten of which are individually mounted on heavy-weight paper or similar material.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications, HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action FDA may take action to withdraw the application.

The drug may not be legally marketed until you have been notified in writing that the application is approved.

If you have any questions, please contact Kati Johnson, Consumer Safety Officer, at (301) 443-0487.

Sincerely yours,

/S/ 2/19/97

Paula Botstein, M.D.
Acting Director
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure: Draft Labeling

cc:

Original NDA 20-624
HFD-180/Div. Files
HFD-002/ORM
HFD-92/DDM-DIAB
HFD-180/K.Johnson
HFD-180/
HFD-103/Office Director
HFD-101/L.Carter
DISTRICT OFFICE
HFD-40/DDMAC (with draft labeling)

2/19/97

Drafted by: kj/February 6, 1997/c:\wpfiles\cso\n\20624702.1kj

APPROVABLE (AE)